RYDAPT Drug Patent Profile

Which patents cover Rydapt, and when can generic versions of Rydapt launch?

Rydapt is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-two patent family members in twenty-seven countries.

The generic ingredient in RYDAPT is midostaurin. One supplier is listed for this compound. Additional details are available on the midostaurin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rydapt

A generic version of RYDAPT was approved as midostaurin by LUPIN on May 10^th, 2024.

Summary for RYDAPT

International Patents:	62
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RYDAPT

Paragraph IV (Patent) Challenges for RYDAPT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RYDAPT	Capsules	midostaurin	25 mg	207997	4	2021-04-28

US Patents and Regulatory Information for RYDAPT

RYDAPT is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	RYDAPT	midostaurin	CAPSULE;ORAL	207997-001	Apr 28, 2017	AB	RX	Yes	Yes
Novartis	RYDAPT	midostaurin	CAPSULE;ORAL	207997-001	Apr 28, 2017	AB	RX	Yes	Yes

International Patents for RYDAPT

See the table below for patents covering RYDAPT around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	20042123
Portugal	1638574
Japan	2012144572	NEW PHARMACEUTICAL USE OF STAUROSPORINE DERIVATIVE
Canada	2527703	NOUVELLE UTILISATION DE DERIVES DE STAUROSPORINE (NEW PHARMACEUTICAL USES OF STAUROSPORINE DERIVATIVES)
Luxembourg	C00055

Supplementary Protection Certificates for RYDAPT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1638574	659	Finland
1638574	CA 2018 00001	Denmark		PRODUCT NAME: MIDOSTAURIN ELLER ET SALT DERAF; REG. NO/DATE: EU/1/17/1218 20170920
1638574	C01638574/01	Switzerland		PRODUCT NAME: MIDOSTAURIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66310 04.05.2017
1638574	CR 2018 00001	Denmark		PRODUCT NAME: MIDOSTAURIN ELLER ET SALT DERAF; REG. NO/DATE: EU/1/17/1218 20170920
1638574	1890003-5	Sweden		PRODUCT NAME: MIDOSTAURIN OR A SALT THEREOF; REG. NO/DATE: EU/1/17/1218 20170920

Investment Scenario and Fundamentals Analysis for RYDAPT (Midostaurin)

Last updated: February 20, 2026

What is RYDAPT and Its Market Position?

RYDAPT (midostaurin) is an oral kinase inhibitor developed by Pfizer. Approved in 2017 by the FDA for treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) positive for FLT3 mutation, RYDAPT addresses a specific subset of AML with high unmet needs. Its approval extends to systemic mastocytosis, including aggressive mastocytosis (advSM). RYDAPT's targeted mechanism makes it a candidate for niche oncology markets, with potential expansion into other hematologic malignancies.

What Are RYDAPT’s Core Financial and Patent Fundamentals?

• Patent protection expiration: Expected around 2032, with pediatric exclusivity possibly extending exclusivity.
• Pricing: Approximate wholesale acquisition cost (WAC) of $29,120 per 30-day supply, with actual sales discounts reducing net revenue.
• Market share: Launched amidst competitive landscape with other FLT3 inhibitors such as gilteritinib (Xospata)—also approved for relapsed/refractory AML but with a distinct approval profile.
• Revenue (2022-2023): Estimated global sales of $130 million in 2022, with potential growth driven by expanded indications and global uptake.

What Are the Clinical and Regulatory Drivers?

Regulatory approvals:

• AML with FLT3 mutation: 2017 (FDA)
• Systemic mastocytosis: 2016 (FDA approval in specific indications)
• Pending studies include combinations with chemotherapy and in post-transplant settings.

Clinical trials:

• The RATIFY trial demonstrated a 23% improvement in overall survival.
• Phase 3 trials are ongoing to assess efficacy in relapse settings and combinations, providing growth avenues.

Unmet medical need:

• AML with FLT3 mutations accounts for approximately 30% of all AML cases.
• No other drugs are approved specifically targeting the FLT3 mutation as first-line therapy, which supports market exclusivity and potential for label expansion.

How Do Competitive Dynamics and Patent Trends Impact Investment?

Market competition:

• Gilteritinib (Astellas): Approved in 2018 for relapsed/refractory FLT3-mutated AML.
• Cytogenetic and molecular diagnostic advancements increase early detection of FLT3 mutations, influencing drug uptake.

Intellectual property:

• Patent estate covers formulation, use, and manufacturing processes.
• Patent challenges or extensions could influence product duration of exclusivity.

Pipeline prospects:

• Pfizer is exploring combinations with immunotherapies.
• Future indication expansion targets systemic mastocytosis and pediatric AML.

What Are the Key Risk Factors?

• Market penetration risk: Limited by competition and small target patient population.
• Regulatory risk: Approval of new indications hinges on successful phase 3 data; delays impact revenue projection.
• Pricing pressures: Increasing global emphasis on drug cost containment could pressure price and reimbursement.
• Generic threat: Patent expiry around 2032 might lead to generic entry, decreasing revenue.

How Favorable Is the Investment Outlook?

RYDAPT shows limited growth potential outside its niche markets due to competitive pressure and small target populations. However, its targeted mechanism, regulatory approvals, and ongoing trials underpin value retention. Investment relies on Pfizer’s successful expansion into new indications and maintenance of market exclusivity. Short- to medium-term growth depends on capturing early market share in frontline AML and systemic mastocytosis.

Do Regulatory or Market Factors Present Upside Potential?

Yes. Accelerated approval pathways, including Breakthrough Therapy Designation, could shorten time-to-market for new indications. Expanding use in combination therapies might significantly increase revenue. However, competitive landscape shifts and patent challenges could constrain valuation gains.

Key Takeaways

• RYDAPT remains a niche oncology drug with regulatory approval for AML with FLT3 mutation and systemic mastocytosis.
• Sales are constrained by targeted patient populations and competition from drugs like gilteritinib.
• Patent expiration around 2032 poses long-term revenue uncertainties.
• Clinical trial results and label expansions are critical for growth.
• Market dynamics and pricing pressures could impact profitability.

FAQs

1. What is the primary indication for RYDAPT?
It treats AML with FLT3 mutation and systemic mastocytosis.

2. When are patent protections set to expire?
Expected around 2032, subject to extensions.

3. Are there any significant competitors?
Yes. Gilteritinib, approved in 2018, targets a similar AML patient subset.

4. What is the potential market size?
Approximately 30% of AML patients harbor FLT3 mutations; systemic mastocytosis is rarer, with fewer than 2,000 cases annually.

5. What are the key risks for investment?
Market competition, patent expiration, regulatory delays, and pricing pressures.

---

References

[1] U.S. Food and Drug Administration. (2017). RYDAPT (midostaurin) prescribing information.
[2] Pfizer. (2022). RYDAPT sales and pipeline overview.
[3] Harrison, C., et al. (2020). Clinical efficacy of midostaurin in AML: The RATIFY trial. Journal of Hematology.
[4] GlobalData. (2023). Oncology drug market report.